Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ethacrynic acid, torsemide, ethacrynate sodium +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3632
Sealed predictions
- SLC12A1 in dopamine neurons, braak+0.63 (p 0.067) → +0.56 (p 0.116)receipt 3640
Swarm cases
receipt 3640: SLC12A1 in dopamine neurons, braak
- power
- full sample +0.72 (p 7.0e-4, n 18), 95% CI +0.39 to +0.89. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.72 (p 7.0e-4, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.74 (p 4.7e-4, n 18). not the mix.
- skeptic
- leave-one-out range +0.69 to +0.79, sign flips 0; without severely affected donors +0.72 (p 7.0e-4, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC12A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts